1
|
Dimaras H, Dimba EAO and Gallie BL:
Challenging the global retinoblastoma survival disparity through a
collaborative research effort. Br J Ophthalmol. 94:1415–1416. 2010.
View Article : Google Scholar : PubMed/NCBI
|
2
|
Narang S, Mashayekhi A, Rudich D and
Shields CL: Predictors of long-term visual outcome after
chemoreduction for management of intraocular retinoblastoma. Clin
Exp Ophthalmol. 40:736–742. 2012. View Article : Google Scholar : PubMed/NCBI
|
3
|
Croce CM: Causes and consequences of
microRNA dysregulation in cancer. Nat Rev Genet. 10:704–714. 2009.
View Article : Google Scholar : PubMed/NCBI
|
4
|
Bartel DP: MicroRNAs: Target recognition
and regulatory functions. Cell. 136:215–233. 2009. View Article : Google Scholar : PubMed/NCBI
|
5
|
Zhuang LK, Xu GP, Pan XR, Lou YJ, Zou QP,
Xia D, Yan WW, Zhang YT, Jia PM and Tong JH: MicroRNA-181a-mediated
downregulation of AC9 protein decreases intracellular cAMP level
and inhibits ATRA-induced APL cell differentiation. Cell Death Dis.
5:e11612014. View Article : Google Scholar : PubMed/NCBI
|
6
|
Zhang B, Pan X, Cobb GP and Anderson TA:
microRNAs as oncogenes and tumor suppressors. Dev Biol. 302:1–12.
2007. View Article : Google Scholar
|
7
|
Liu S, Hu C, Wang Y, Shi G, Li Y and Wu H:
miR-124 inhibits proliferation and invasion of human retinoblastoma
cells by targeting STAT3. Oncol Rep. 36:2398–2404. 2016. View Article : Google Scholar : PubMed/NCBI
|
8
|
Wang J, Wang X, Li Z, Liu H and Teng Y:
MicroRNA-183 suppresses retinoblastoma cell growth, invasion and
migration by targeting LRP6. FEBS J. 281:1355–1365. 2014.
View Article : Google Scholar
|
9
|
Shen F, Mo M-H, Chen L, An S, Tan X, Fu Y,
Rezaei K, Wang Z, Zhang L and Fu SW: MicroRNA-21 Down-regulates Rb1
expression by targeting PDCD4 in retinoblastoma. J Cancer.
5:804–812. 2014. View Article : Google Scholar : PubMed/NCBI
|
10
|
Huang YX, Nie XG, Li GD, Fan DS, Song LL
and Zhang XL: Downregulation of microRNA-182 inhibits cell
viability, invasion and angiogenesis in retinoblastoma through
inhibition of the PI3K/AKT pathway and CADM2 upregulation. Int J
Oncol. 53:2615–2626. 2018.PubMed/NCBI
|
11
|
Sun Z, Zhang A, Jiang T, Du Z, Che C and
Wang F: miR-145 suppressed human retinoblastoma cell proliferation
and invasion by targeting ADAM19. Int J Clin Exp Pathol.
8:14521–14527. 2015.
|
12
|
Ting H-J, Messing J, Yasmin-Karim S and
Lee Y-F: Identification of microRNA-98 as a therapeutic target
inhibiting prostate cancer growth and a biomarker induced by
vitamin D. J Biol Chem. 288:1–9. 2013. View Article : Google Scholar :
|
13
|
Hebert C, Norris K, Scheper MA, Nikitakis
N and Sauk JJ: High mobility group A2 is a target for miRNA-98 in
head and neck squamous cell carcinoma. Mol Cancer. 6:52007.
View Article : Google Scholar : PubMed/NCBI
|
14
|
Siragam V, Rutnam ZJ, Yang W, Fang L, Luo
L, Yang X, Li M, Deng Z, Qian J, Peng C, et al: MicroRNA miR-98
inhibits tumor angiogenesis and invasion by targeting activin
receptor-like kinase-4 and matrix metalloproteinase-11. Oncotarget.
3:1370–1385. 2012. View Article : Google Scholar : PubMed/NCBI
|
15
|
Edge SB and Compton CC: The American Joint
Committee on Cancer: the 7th edition of the AJCC cancer staging
manual and the future of TNM. Ann Surg Oncol. 17:1471–1474. 2010.
View Article : Google Scholar : PubMed/NCBI
|
16
|
Chantada G, Doz F, Antoneli CB, Grundy R,
Clare Stannard FF, Dunkel IJ, Grabowski E, Leal-Leal C,
Rodríguez-Galindo C, Schvartzman E, et al: A proposal for an
international retino-blastoma staging system. Pediatr Blood Cancer.
47:801–805. 2006. View Article : Google Scholar
|
17
|
Livak KJ and Schmittgen TD: Analysis of
relative gene expression data using real-time quantitative PCR and
the 2(-∆ ∆ C(T)) Method. Methods. 25:402–408. 2001. View Article : Google Scholar
|
18
|
Lai YJ, Lin CI, Wang CL and Chao JI:
Expression of survivin and p53 modulates honokiol-induced apoptosis
in colorectal cancer cells. J Cell Biochem. 115:1888–1899.
2014.PubMed/NCBI
|
19
|
Duan J, Li X, Huang S, Zeng Y, He Y, Liu
H, Lin D, Lu D and Zheng M: GOLPH2, a gene downstream of ras
signaling, promotes the progression of pancreatic ductal
adenocarcinoma. Mol Med Rep. 17:4187–4194. 2018.PubMed/NCBI
|
20
|
Hood JD and Cheresh DA: Role of integrins
in cell invasion and migration. Nat Rev Cancer. 2:91–100. 2002.
View Article : Google Scholar
|
21
|
Bergers G, Brekken R, McMahon G, Vu TH,
Itoh T, Tamaki K, Tanzawa K, Thorpe P, Itohara S, Werb Z, et al:
Matrix metallopro-teinase-9 triggers the angiogenic switch during
carcinogenesis. Nat Cell Biol. 2:737–744. 2000. View Article : Google Scholar : PubMed/NCBI
|
22
|
Kang Y and Massagué J:
Epithelial-mesenchymal transitions: Twist in development and
metastasis. Cell. 118:277–279. 2004. View Article : Google Scholar : PubMed/NCBI
|
23
|
Natalwala A, Spychal R and Tselepis C:
Epithelial-mesenchymal transition mediated tumourigenesis in the
gastrointestinal tract. World J Gastroenterol. 14:3792–3797. 2008.
View Article : Google Scholar : PubMed/NCBI
|
24
|
Hur K, Toiyama Y, Takahashi M, Balaguer F,
Nagasaka T, Koike J, Hemmi H, Koi M, Boland CR and Goel A:
MicroRNA-200c modulates epithelial-to-mesenchymal transition (EMT)
in human colorectal cancer metastasis. Gut. 62:1315–1326. 2013.
View Article : Google Scholar :
|
25
|
Li JZ-H, Gao W, Lei W-B, Zhao J, Chan JY,
Wei WI, Ho WK and Wong TS: MicroRNA 744-3p promotes MMP-9-mediated
metastasis by simultaneously suppressing PDCD4 and PTEN in
laryngeal squamous cell carcinoma. Oncotarget. 7:58218–58233.
2016.PubMed/NCBI
|
26
|
Chen L, Wang Q, Wang GD, Wang HS, Huang Y,
Liu XM and Cai XH: miR-16 inhibits cell proliferation by targeting
IGF1R and the Raf1-MEK1/2ERK1/2 pathway in osteosarcoma. FEBS Lett.
587:1366–1372. 2013. View Article : Google Scholar : PubMed/NCBI
|
27
|
Rupaimoole R and Slack FJ: MicroRNA
therapeutics: Towards a new era for the management of cancer and
other diseases. Nat Rev Drug Discov. 16:203–222. 2017. View Article : Google Scholar : PubMed/NCBI
|
28
|
Calin GA and Croce CM: MicroRNA signatures
in human cancers. Nat Rev Cancer. 6:857–866. 2006. View Article : Google Scholar : PubMed/NCBI
|
29
|
Lu J, Getz G, Miska EA, Alvarez-Saavedra
E, Lamb J, Peck D, Sweet-Cordero A, Ebert BL, Mak RH, Ferrando AA,
et al: MicroRNA expression profiles classify human cancers. Nature.
435:834–838. 2005. View Article : Google Scholar : PubMed/NCBI
|
30
|
Yang Y and Mei Q: miRNA signature
identification of retino-blastoma and the correlations between
differentially expressed miRNAs during retinoblastoma progression.
Mol Vis. 21:1307–1317. 2015. View Article : Google Scholar
|
31
|
Beta M, Venkatesan N, Vasudevan M,
Vetrivel U, Khetan V and Krishnakumar S: Identification and
insilico analysis of retino-blastoma serum microRNA profile and
gene targets towards prediction of novel serum biomarkers.
Bioinform Biol Insights. 7:21–34. 2013. View Article : Google Scholar :
|
32
|
Wu X, Zeng Y, Wu S, Zhong J, Wang Y and Xu
J: miR-204, down-regulated in retinoblastoma, regulates
proliferation and invasion of human retinoblastoma cells by
targeting cyclin D2 and MMP-9. FEBS Lett. 589:645–650. 2015.
View Article : Google Scholar : PubMed/NCBI
|
33
|
Venkatesan N, Deepa PR, Khetan V and
Krishnakumar S: Computational and in vitro investigation of
miRNA-gene regulations in retinoblastoma pathogenesis: miRNA mimics
strategy. Bioinform Biol Insights. 9:89–101. 2015. View Article : Google Scholar : PubMed/NCBI
|
34
|
Shields CL and Shields JA: Retinoblastoma
management: Advances in enucleation, intravenous chemoreduction,
and intra-arterial chemotherapy. Curr Opin Ophthalmol. 21:203–212.
2010. View Article : Google Scholar : PubMed/NCBI
|
35
|
Yang J and Weinberg RA:
Epithelial-mesenchymal transition: At the crossroads of development
and tumor metastasis. Dev Cell. 14:818–829. 2008. View Article : Google Scholar : PubMed/NCBI
|
36
|
Jou J and Diehl AM: Epithelial-mesenchymal
transitions and hepatocarcinogenesis. J Clin Invest. 120:1031–1034.
2010. View Article : Google Scholar : PubMed/NCBI
|
37
|
Zhou H, Huang Z, Chen X and Chen S: miR-98
inhibits expression of TWIST to prevent progression of non-small
cell lung cancers. Biomed Pharmacother. 89:1453–1461. 2017.
View Article : Google Scholar : PubMed/NCBI
|
38
|
Annunziata L, Li G and Pellecchia C: Group
4 metal bis(chelate) complexes of 2-anilidomethylpyridine ligands:
Synthesis and catalytic activity for olefin polymerization. J Mol
Catal Chem. 337:1–8. 2011. View Article : Google Scholar
|
39
|
Durfort T, Tkach M, Meschaninova MI, Rivas
MA, Elizalde PV, Venyaminova AG, Schillaci R and François JC: Small
interfering RNA targeted to IGF-IR delays tumor growth and induces
proin-flammatory cytokines in a mouse breast cancer model. PLoS
One. 7:e292132012. View Article : Google Scholar
|
40
|
Zhao X, Dou W, He L, Liang S, Tie J, Liu
C, Li T, Lu Y, Mo P, Shi Y, et al: MicroRNA-7 functions as an
anti-metastatic microRNA in gastric cancer by targeting
insulin-like growth factor-1 receptor. Oncogene. 32:1363–1372.
2013. View Article : Google Scholar
|
41
|
Du Y, Li Y, Lv H, Zhou S, Sun Z and Wang
M: miR-98 suppresses tumor cell growth and metastasis by targeting
IGF1R in oral squamous cell carcinoma. Int J Clin Exp Pathol.
8:12252–12259. 2015.
|
42
|
Kent OA, Fox-Talbot K and Halushka MK:
RREB1 repressed miR-143/145 modulates KRAS signaling through
downregulation of multiple targets. Oncogene. 32:2576–2585. 2013.
View Article : Google Scholar
|
43
|
Na KY, Kim YW and Park Y-K:
Mitogen-activated protein kinase pathway in osteosarcoma.
Pathology. 44:540–546. 2012. View Article : Google Scholar : PubMed/NCBI
|
44
|
Zhang J-J, Chen J-T, Hua L, Yao K-H and
Wang C-Y: miR-98 inhibits hepatocellular carcinoma cell
proliferation via targeting EZH2 and suppressing Wnt/β-catenin
signaling pathway. Biomed Pharmacother. 85:472–478. 2017.
View Article : Google Scholar
|
45
|
Ni R, Huang Y and Wang J: miR-98 targets
ITGB3 to inhibit proliferation, migration, and invasion of
non-small-cell lung cancer. Onco Targets Ther. 22:2689–2697.
2015.
|
46
|
Wu L, Xiao B and Chai Y: Overexpression of
miR-98 inhibits cell invasion in glioma cell lines via
downregulation of IKK ε. Eur Rev Med Pharmacol Sci. 19:3593–3604.
2015.
|